Aurora Investment Counsel Sells 12,753 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Aurora Investment Counsel reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,350 shares of the biopharmaceutical company's stock after selling 12,753 shares during the quarter. Aurora Investment Counsel's holdings in Halozyme Therapeutics were worth $1,852,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Congress Asset Management Co. grew its position in Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock valued at $139,298,000 after purchasing an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company's stock worth $112,715,000 after buying an additional 856,200 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Halozyme Therapeutics by 12.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock valued at $99,363,000 after acquiring an additional 209,530 shares in the last quarter. Epoch Investment Partners Inc. increased its position in shares of Halozyme Therapeutics by 23.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company's stock valued at $58,319,000 after acquiring an additional 270,579 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in Halozyme Therapeutics by 9.7% during the second quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company's stock worth $43,002,000 after acquiring an additional 72,544 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Trading Up 2.1 %

Shares of HALO stock opened at $45.76 on Thursday. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53. The company has a market capitalization of $5.82 billion, a PE ratio of 15.15, a price-to-earnings-growth ratio of 0.41 and a beta of 1.29. The firm has a 50 day moving average price of $55.15 and a two-hundred day moving average price of $53.48. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on HALO shares. Wells Fargo & Company downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and raised their price target for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Cowen reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Benchmark restated a "buy" rating and set a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and increased their price target for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, Morgan Stanley boosted their price objective on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 7th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.11.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total value of $525,800.00. Following the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $35,583,199.52. This represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 60,000 shares of company stock worth $3,425,000. Company insiders own 2.40% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.